Introduction {#s02}
============

T lymphocytes as cytotoxic agents against cancer cells {#s03}
------------------------------------------------------

One of the infrequently heralded breakthroughs of the 1960s was the observation that cells of the adaptive immune system could be divided into two broad functional classes: B and T lymphocytes or, simply, B and T cells ([@bib60]; [@bib12]). We will focus on T cells, which are important for immunotherapy because they secrete cytokines and generate cytotoxic reactions against other cells that are infected with viruses or are cancerous ([@bib61]; [@bib58]). The body has a large repertoire of T cells, each with a unique TCR that recognizes antigen as short peptides bound to MHC proteins on the surface of APCs. These antigen/MHC complexes, especially when unique to tumor cells, are the key signal for T cells to attack. By either enhancing the initial recognition and immune response to cancer antigens or thwarting peripheral tolerance "checkpoints," or both, cancer immunotherapies generate and sustain tumoricidal immunity.

Peripheral tolerance of T cells {#s04}
-------------------------------

Tolerance is the ability of T cells to generally ignore antigens endogenous or harmless to the host and mount strong reactions only to foreign and pathogenic antigens. Failure of tolerance can cause a range of autoimmune diseases and great human suffering, although most people go through life without much obvious or permanent damage from T cell immunity. Mechanisms have evolved in T cells to ensure specific and controlled responses that involve tolerance (limited responsiveness) to self. One mechanism to prevent autoimmune responses is to eliminate autoreactive T cells during development, i.e., central tolerance. Other mechanisms restrain, neutralize, or eliminate mature T cells in the periphery when they engage antigens, i.e., peripheral tolerance ([@bib62]; [@bib53]). To begin, MHC-presented peptides will generally activate naive T cells only if "costimulatory" signals are received through CD28 or allied molecules. The ligands for CD28, B7-1 (CD80), and B7-2 (CD86) are restricted to specific "professional" APCs and are induced by pathogen-specific signals operating through TLRs and other sensors for molecules from dangerous microbes. Hence, the incoming signal is evaluated for a likely correspondence to pathogens, and a go/no-go decision is made. This is a true "checkpoint" for T cell reactivity. In fact, strong stimulation through the TCR without costimulation paralyzes T cells in a nonresponsive state called "anergy." Anergy may contribute to peripheral tolerance to antigens seen again and again, a key feature of "self" antigens.

To promote a therapeutic anticancer response, CD8^+^ T cells that are strongly activated by tumor antigens must be unrestrained by negative regulators. A fundamental problem in biological systems is that a priori information is often lacking about how much stimulus will be encountered in order to gauge an appropriately measured reaction. Given that the immune system is confronted daily with rapidly growing microorganisms, it is a constant challenge to ensure an effective pathogen response while limiting overkill that damages host tissues. Evolution has countered with cybernetic or feedback control systems in which the initial stimulus triggers negative regulators that dampen the response ([@bib53]). As described below, these negative regulators are proportionately engaged by the strength of stimulation, and have been called "checkpoints" since they detect, resist, and reverse overactivation. By creating negative feedback, immune checkpoints vouchsafe more uniform and controlled immune reactions to prevent collateral damage.

Immune checkpoint therapy {#s05}
=========================

Cytotoxic T lymphocyte--associated protein 4 (CTLA-4) biology {#s06}
-------------------------------------------------------------

CTLA-4 is a member of the CD28 family of receptors that is induced on the cell surface on conventional T cells by antigen activation and constitutively expressed on regulatory T (T reg) cells, a specialized subset of CD4^+^ T cells that can arrest T cell responses ([@bib99]). It negatively regulates costimulatory signaling and powerfully enforces peripheral tolerance. CD28 and CTLA-4 compete for binding to B7-1 and B7-2 on APCs, including B lymphocytes, dendritic cells, and other immune cells. As the cousin of CD28, which provides the critical cosignal required for TCR-mediated proliferation, survival, and cytokine production, CTLA-4 has evolved to counterbalance these costimulatory signals since it can bind B7-1/B7-2 more tightly, but delivers negative rather than costimulatory signals to the T cell ([Fig. 1](#fig1){ref-type="fig"}; [@bib121]). CTLA-4 is part of a built-in tolerance algorithm involving its induction with a delay, but in proportion to T cell activation. This allows it to suppress apparently spontaneous T cell reactions against self-antigens and diminish the intensity of responses to foreign antigens. Genetic CTLA-4 deficiency in mice and humans wreaks immune havoc with severe lymphoproliferation and clonal senescence, lymphocytic infiltration into the lungs, brain, and gastrointestinal tract, autoimmunity, hypogammaglobulinemia, respiratory tract infections, and enteropathy. Loss of costimulation control is the culprit, since immunopathology can be circumvented in CTLA-4--deficient mice by either blocking B7 ligand interactions with a soluble CTLA-4--immunoglobulin fusion protein or by crossing CTLA-4--deficient mice to B7-deficient mice ([@bib112]; [@bib57]). Not surprisingly, therapy with anti--CTLA-4 causes colitis as a major side effect ([@bib111]; [@bib123]; [@bib46]; [@bib102]). By contrast, clinical improvement has been observed when abatacept, a Food and Drug Administration (FDA)--approved CTLA-4--immunoglobulin fusion protein drug, is administered to humans suffering from CTLA-4--haploinsufficiency with autoimmunity and infiltration disease, a genetic deficiency of CTLA-4 ([@bib52]). The effectiveness of soluble CTLA-4 is because it competes for CD28 ligands on the surface of APCs. These soluble forms, like CTLA-4 itself, associate with B7-1 and B7-2 with higher affinity and avidity than CD28 ([@bib118]; [@bib11]). Imaging analyses pinpoint CTLA-4 accumulation in the immunological synapse, where it interferes with CD28 recruitment and downstream signaling ([@bib130]). Other studies show CTLA-4 consorting with the TCR in lipid rafts to form lattice-like structures that inhibit CD28 signaling ([@bib13]).

![**Mechanisms of CTLA-4 function and inhibition. (A--C)** CTLA-4 is up-regulated on activated T cells and inhibits further T cell activation by competing with CD28 for B7 ligation. T reg cells, which constitutively express CTLA-4, trans-endocytose B7 ligands on APCs to prevent CD28 costimulation. **(D)** Blocking CTLA-4 results in enhanced CD28-B7 ligation, which unleashes T cell expansion and effector function. By inhibiting CTLA-4 on T reg cells, B7 trans-endocytosis is suppressed, resulting in increased APC potency. CTLA-4 blockade is also thought to cause T reg cell depletion through ADCC by cells expressing Fcγ receptors.](JEM_20182395_Fig1){#fig1}

In addition to encumbering CD28 signaling, CTLA-4 engagement induces negative signals ([@bib44]; [@bib122]). The cytoplasmic domain of CTLA-4 attracts several members of the PP2A family of serine/threonine phosphatases that disengage downstream TCR signaling ([@bib51]; [@bib10]). CTLA-4 can also run interference by interacting directly with the TCR and prevent its tyrosine phosphorylation following stimulation ([@bib51]). Finally, CTLA-4 may strike at the heart of the proliferation machinery by decreasing ERK activity and increasing JNK in T cells ([@bib6]; [@bib101]). Hence, CTLA-4 counteracts several internal signaling nodes to impede activation and proliferation of T cells.

Several studies suggest that additional functions of CTLA-4 may be T cell--extrinsic ([@bib121]). Hints initially came from the surprising observation that RAG2-deficient mice transplanted with a mixture of normal and CTLA-4--deficient bone marrow do not develop lymphoproliferative disease ([@bib3]). Something from the normal marrow apparently suppressed the unrestrained immune reactions typically caused by CTLA-4--deficient bone marrow. Later studies showed that T reg cells suppress dendritic cell function by decreasing B7-1 and B7-2 expression ([@bib63]; [@bib69]; [@bib128]; [@bib84]). This led to the fascinating discovery that CTLA-4 could pluck B7-1 and B7-2 from the surface of APCs and send them to lysosomes within the T reg cells, a process called trans-endocytosis ([@bib84]; [@bib43]). This leaves the APCs without costimulatory ability.

CTLA-4 deficiency in mice and humans debilitates the tolerance mechanisms described above, thereby fooling T cells into activation and migration into organs as though they were chasing an infection ([@bib128]). All of the cell-intrinsic and -extrinsic tolerance mechanisms required CTLA-4 to evolve a multifaceted toolbox to restrain T cells following antigen engagement. However, the fact that CTLA-4 operates at the cell surface suggested a simple strategy for boosting T cell immunity by using a CTLA-4 inhibitory antibody. This inspired a new mode of cancer treatment that could work in the absence of any knowledge of tumor antigens ([@bib50]).

Development of CTLA-4 blockade for cancer therapy {#s07}
-------------------------------------------------

Allison and colleagues first demonstrated that administering CTLA-4 blocking antibodies in mice prevented tumor establishment and induced the rejection of preestablished tumors. They also demonstrated immunological memory; mice continued to be able to reject tumor cells if they had once rejected the tumor with anti--CTLA-4 therapy. Moreover, rejection depended on immunogenicity of the tumor ([@bib50]; [@bib47]). The preclinical success in experimental animals led to the development and testing of fully humanized monoclonal antibodies against CTLA-4 that prevent its interaction with B7 ligands (tremelimumab and ipilimumab) in humans with advanced cancer ([@bib32]). Early clinical trials of CTLA-4 blockade showed disease regression in patients with various tumor types ([@bib30]; [@bib77]; [@bib87]; [@bib17]). These studies also showed that there was a price to be paid for breaching tolerance, e.g., severe autoimmune reactions that led to early termination of certain studies ([@bib77]). A large phase III trial demonstrated that ipilimumab increased the median overall survival of metastatic melanoma patients to 10.0 mo compared with 6.4 mo in patients treated with the peptide vaccine gp100 ([@bib31]). Notably, later follow-up studies revealed that ∼20% of patients treated with ipilimumab survived for ≥3 yr ([@bib100]). Ipilimumab also compared favorably to standard chemotherapy ([@bib91]). The FDA approved ipilimumab for the treatment of metastatic melanoma in 2011. Given the success of ipilimumab, it is puzzling and frustrating that tremelimumab has not had the same efficacy. In a phase III trial, tremelimumab was no better in advanced melanoma patients than standard chemotherapy ([@bib88]). Clinical trials testing tremelimumab in other cancer types (mesothelioma and non--small cell lung cancer) were also unsuccessful. The discrepancy between ipilimumab and tremelimumab may be due to mechanistic or structural differences in the antibody molecules ([@bib23]; [@bib28]). To date, tremelimumab monotherapy has not obtained FDA approval, although combinatorial therapies with tremelimumab are being evaluated. Overall, inhibiting CTLA-4 with ipilimumab has caused a paradigm shift in cancer therapy by successfully mobilizing the immune response against tumors. As an orthogonal approach, checkpoint immunotherapy has been effective in tumors like melanoma that responded poorly to conventional chemotherapy. Although this form of immunotherapy has been a groundbreaking achievement, it is not a panacea. Not all patients or cancer types respond, underscoring the need for a greater basic understanding of antitumor immunity.

Mechanisms of CTLA-4 blockade in tumor regression {#s08}
=================================================

The simplest explanation behind anti--CTLA-4 immunotherapy is that T cells exist that recognize tumor antigens, including neoantigens resulting from somatic gene mutations in the tumor cell genomes. Possibly because these antigens are too close to self-antigens or they are presented by poorly costimulatory tumor cells, or other reasons, cytotoxic T cells need a kick-start from CTLA-4 blockade. There are many variations of this theme, but the key idea is that taking the brakes off T cell activation causes greater tumoricidal action. Ipilimumab has been shown to mask the epitope that binds to B7 ligands, suggesting that CTLA-4 blockade inhibits the crucial interaction that normally suppresses T cell responses ([@bib85]). Preventing CTLA-4--B7 interactions not only fortifies effector T cells but may also modulate the suppressive function and/or presence of T reg cells ([Fig. 1](#fig1){ref-type="fig"}).

One pertinent question is how this relates to the classical idea of tumor immunosurveillance. In other words, is the eradication of malignant cells a primary capability that the immune system has evolved to do, or are we artificially borrowing the cytolytic power that protects against infections? One observation to consider is that neither primary nor acquired immunodeficiency leads to an outbreak of solid tumors. For example, the AIDS epidemic, which has affected millions of people worldwide, is not associated with an excess of common epithelial cancers ([@bib25]). In fact, malignancies that usually arise can be attributed to oncogenic viruses that are uncontrolled. On the other hand, breaching peripheral T cell tolerance by anti--CTLA-4 therapy causes a whole range of intense immune reactions that injure host and cancer cells alike. Nonetheless, a firm answer to this question will require additional molecular investigation of immune responses during checkpoint therapy.

Enhanced T effector function {#s09}
----------------------------

CTLA-4 blockade unleashes potent antitumor T cell responses, but the specificity and phenotype of these T cells under different treatment settings are not fully understood. Recent studies have indicated that immunotherapy can bolster specific T cell responses to neoantigens, peptides unique to the cancer genome arising from spontaneous or carcinogen-derived mutations in DNA ([@bib120]). [@bib59] demonstrated that melanoma and non--small cell lung cancer patients with the highest burden of clonal neoantigens had the most durable responses to checkpoint blockade. Other studies have also reported a correlation between mutational load and response to immunotherapy ([@bib106]; [@bib90]; [@bib117]). The implication of these studies, albeit indirect, is that a higher burden of mutations translates into more tumor-specific neoantigens, which can then be targeted by T cells. Obviously, there are a lot of links in this hypothetical mechanistic chain. Neoantigens require greater investigation through genomic and biochemical approaches. Personalized vaccines against neoantigens are becoming a viable therapeutic option and were the subject of recent review ([@bib98]). This strategy could be conjoined with checkpoint inhibition to further boost antitumor immune responses and improve patient outcome.

The phenotypic profile of T cells that infiltrate tumors during checkpoint blockade has been partly characterized using mass spectrometry--driven methods and shows differential expression of markers involved in activation, development, and exhaustion ([@bib20]; [@bib125]). For example, neoantigen-specific CD8^+^ T cells in tumor-bearing mice that received either anti--CTLA-4 or anti--programmed cell death protein-1 (PD-1); PD-1 therapy had reduced expression of markers associated with T cell dysfunction (PD-1 and glucocorticoid-induced TNFR-related protein) and increased markers of T cell activation and development (stem cell antigen-1; [@bib20]). Tumor immune infiltrates in human melanoma contain CD8^+^ T cells with an exhausted phenotype expressing PD-1 and T cell immunoglobulin mucin 3 (TIM3), and, curiously, a subset of effector CD4^+^ T cells that express PD-1 and inducible T cell costimulator (ICOS), markers that typically define T follicular helper cells ([@bib125]). Also, the phenotypic profile of intratumoral T cells in human melanoma patients differed depending on the type of checkpoint blockade. Both anti--CTLA-4 and anti--PD-1 therapy induced the expansion of CD8^+^ T cells expressing PD-1 and TIM3, while anti--CTLA-4 therapy caused a selective increase in CD4^+^, ICOS^+^ effectors. These T helper cell 1--like CD4^+^ cells have been reported in multiple tumor types following ipilimumab treatment ([@bib54]; [@bib9]; [@bib7]; [@bib8]), and may enhance CD8^+^ T cell cytotoxicity and memory development. Thus, CTLA-4 blockade increases effector capabilities, particularly cytotoxicity, of antigen-specific CD8^+^ T cells, and alters T cell differentiation.

Reduced frequency and function of T reg cells {#s10}
---------------------------------------------

Blockade of CTLA-4 on T reg cells may also give free rein to antitumor T cell responses by reducing both T reg cell frequency and suppressive function ([@bib75]). Studies in mice and humans suggest that anti--CTLA-4 therapy depletes T reg cells at the tumor site, although the precise mechanisms are unclear ([@bib54]; [@bib103]; [@bib105]; [@bib110]; [@bib95]). By contrast, T reg cells in secondary lymphoid tissues are increased ([@bib56]; [@bib82]; [@bib68]; [@bib41]). These differences could be explained by higher expression of CTLA-4 by intratumoral T reg cells or increased effector cells in the tumor that mediate T reg cell death, but we don't yet have a compelling explanation for this paradox. T reg cell depletion and antitumor activity are dependent on Fcγ receptors and not C3 expression ([@bib103]; [@bib105]), suggesting antibody-dependent cell-mediated cytotoxicity (ADCC) is involved rather than complement-mediated lysis. IgG1, the isotype of ipilimumab, has high affinity for FcγRIIIa (CD16a), the Fc receptor mediating ADCC ([@bib5]). Interestingly, cancer patients with a high-affinity polymorphism in this receptor had greater responsiveness to ipilimumab therapy ([@bib2]). This lends more weight to the idea that ipilimumab works partly by ADCC. Next-generation ipilimumab antibodies that have increased ADCC activity are currently being tested in preclinical models (Korman, A.J., J. Engelhardt, J. Loffredo, J. Valle, R. Akter, R. Vuyyuru, N. Bezman, P. So, R. Graziano, K. Tipton, et al. 2017. AACR Annual Meeting. Abstr. SY09-01).

T reg cells constitutively express high surface CTLA-4, making them potent antagonists of T cell activation ([@bib86]; [@bib128]; [@bib84]; [@bib34]). Thus, inhibiting CTLA-4 on T reg cells wipes out one of the strongest tolerance enforcers. This is dramatically illustrated in mice engineered to have CTLA-4--deficient T reg cells. Depleting CTLA-4 on that compartment alone causes intense lymphoproliferation and fatal autoimmunity, while heightening antitumor immunity ([@bib128]). Anti--CTLA-4 antibody treatment in mice also neutralizes T reg cells ([@bib86]; [@bib108]). T reg cells are elevated in many human cancers, and this loosely correlates with a worse prognosis ([@bib19]). Suppression of T reg cells has been attempted with both anti-CD25, to starve them of their principal growth factor IL-2, or anti--CTLA-4 ([@bib19]). [@bib56] reported that CD25^+^ T reg cells isolated from patients treated with anti--CTLA-4 antibody retained suppressive function in vitro; thus, if T reg cells survive treatment, at least some of their functions remain intact.

PD-1/PD-L1 biology {#s11}
==================

PD-1 was first discovered by Honjo and colleagues as a member of the immunoglobulin gene superfamily thought to be involved in programmed cell death. It is a transmembrane protein expressed by select thymocyte subsets and T and B lymphocytes, especially after antigen receptor stimulation ([@bib72]). However, detailed studies showed that its biological function was to enfeeble T cell function not by death but by old age. When engaged, it mediates a complex epigenetic and transcriptional transformation in T cells, creating a new hyporesponsive phenotype called "exhaustion" that resembles senescence ([@bib37]; [@bib1]; [@bib70]; [@bib74]). PD-1 is triggered by the B7 homologues, PD-L1 (B7-H1) and PD-L2 (B7-H2), that constitutively reside on nonlymphoid tissues and can be up-regulated in immune cells by proinflammatory cytokines such as IFN-γ and TNF ([Fig. 2](#fig2){ref-type="fig"}; [@bib14]; [@bib22]; [@bib49]; [@bib114]). The critical role for PD-1 in peripheral tolerance was shown in knockout mice that developed lupus-like arthritis and glomerulonephritis (C57BL/6) or autoantibody-mediated dilated cardiomyopathy and thrombosis (BALB/c) depending on the strain ([@bib66], [@bib67]). Tolerance induction by PD-1 is a lymphocyte-intrinsic effect involving phosphorylation of the immunoreceptor tyrosine-based switch motif in its cytoplasmic tail and subsequent recruitment of Src homology 2 (SH2) domain--containing tyrosine phosphatase 2 (SHP-2) in T and B cells ([@bib71]; [@bib104]). However, in contrast to PD-1--deficient mice ([@bib40]), T cells deficient in SHP-2 did not have enhanced antitumor immunity, suggesting other pathways contributed to PD-1 suppression ([@bib97]). Indeed, PD-1 can inhibit phosphorylation of TCR/B cell receptor proximal (CD3ζ, Zap70, Igβ, and Syk) and distal (PKCθ, PLCγ, and ERK1/2) signaling molecules, which prevents calcium mobilization and reprograms T cell metabolism from glycolysis toward fatty acid β-oxidation ([@bib71]; [@bib131]; [@bib119]). Importantly, PD-L1 and PD-L2 are also expressed on myeloid cells present in the tumor microenvironment, and can be up-regulated on malignant cells themselves ([@bib45]; [@bib132]). This type of immunoediting sets up a protective barrier to antitumor immunity by exhausting PD-1 antitumor T cells that approach ([@bib126]). Thus, breaking this mechanism of tumor escape was proposed as a promising strategy for cancer immunotherapy, and paved the way for further examination of inhibiting PD-1/PD-L1 to unleash antitumor immunity ([@bib38]).

![**Mechanisms of PD-1 function and inhibition. (A and B)** PD-1 is expressed by activated T cells and binds to PD-L1 and PD-L2 on APCs or other nonimmune cells to inhibit T cell signaling through a poorly defined mechanism. Chronic T cell signaling results in exhaustion and an inability to properly function. **(C)** PD-1/PD-L1 inhibition unleashes the expansion of CD4^+^ and CD8^+^ T cell populations, resulting in increased memory formation and cytotoxic T cell responses.](JEM_20182395_Fig2){#fig2}

Development of PD-1/PD-L1 blockade for cancer therapy {#s12}
=====================================================

The discovery that PD-1 ligation induces T cell exhaustion meant that inhibiting its engagement might improve immunity against infections or cancer. Preclinical models demonstrated that PD-L1 blockade increased the duration of dendritic cell--T cell interactions and promoted T cell activation in vivo ([@bib21]). Moreover, anti--PD-L1 treatment in tumor-burdened mice resulted in enhanced tumor-specific T cell responses and inhibition of tumor growth ([@bib15]; [@bib38], [@bib39]). The effectiveness of PD-1/PD-L1 inhibition in tumor regression encouraged clinical tests in humans with advanced cancer. The fully human PD-1 (nivolumab) and PD-L1 (MDX-1105 and atezolizumab) monoclonal blocking antibodies showed exciting regression in patients with diverse incurable cancers, including melanoma, non--small cell lung cancer, and renal cell carcinoma ([@bib4]; [@bib113]; [@bib81]). In multiple clinical trials, anti--PD-1 therapy resulted in an overall response rate of 30--40% in patients with otherwise fatal melanoma ([@bib26]; [@bib93]; [@bib124]). One especially hopeful finding was a 26% response rate in melanoma patients whose disease had progressed on ipilimumab ([@bib92]). The FDA approved anti--PD-1 antibodies, nivolumab and pembrolizumab, for melanoma in 2014, and since then, for other malignancies. Atezolizumab became the first PD-L1 inhibitor to receive FDA approval for the treatment of urothelial cancer in 2016 despite an overall response rate of only 15%, which nonetheless exceeded the historical control rate of 10% ([@bib96]). Other PD-L1 inhibitors (avelumab and durvalumab) have also been approved, and treatments with these inhibitors have expanded to include non--small cell lung cancer and Merkel cell carcinoma of the skin.

Mechanisms of PD-1/PD-L1 blockade in tumor regression {#s13}
=====================================================

PD-1 engagement on activated T cells puts the brakes on by causing cell cycle arrest, suppression of T cell migration, and reduced cytolytic mediators ([@bib73]). This has likely evolved to tune down the inflammatory and tissue-destructive capacity of T cells if they remain activated. In the face of an ever-growing tumor, however, PD-1 would blunt the desired antitumor response. Evidence suggests that inhibiting the PD-1/PD-L1 signaling pathway reinvigorates tumor-specific T cells at the tumor site ([Fig. 2](#fig2){ref-type="fig"}). For instance, metastatic melanoma patients responding to anti--PD-1 therapy (pembrolizumab) show exuberant proliferation of intratumoral CD8^+^ T cells correlating with a decrease in tumor size ([@bib115]). Moreover, CD8^+^ T cells (CXCR5^+^PD-1^+^ICOS^+^) expand in response to PD-1 blockade, which correlates with responsiveness to anti--PD-1 therapy ([@bib83]; [@bib42]; [@bib36]). Up-regulated PD-L1 in tumor cell lines following IFN-γ treatment is associated with increased apoptosis of tumor-specific T cells, resulting in greater tumorigenesis in vivo ([@bib15]). Thus, PD-1/PD-L1 inhibition not only promotes expansion, migration, and cytolytic activity of tumor-specific T cells but also may prevent their demise. Not surprisingly, boosting T cell responses with anti-PD-1/PD-L1 therapy was most effective when tumors expressed high levels of PD-L1 ([@bib29]). Also, PD-L1 expression by infiltrating immune cells (dendritic cells, macrophages, and T cells) was particularly important for responsiveness to anti--PD-L1 therapy in multiple cancer types ([@bib29]).

Although it is chiefly CD8^+^ T cells that recover function and proliferate after anti--PD-1/PD-L1 therapy, CD4^+^ T cells may also be rescued. The classic conception holds that CD4^+^ T cells are required to produce stimulatory cytokines for primary CD8^+^ T cell responses and/or CD8^+^ memory formation ([@bib127]). Activated CD4^+^ T cells also secrete IFN-γ and chemokines that enhance vascular permeability and migration of cytotoxic T cells and antibodies into peripheral tissues ([@bib64]; [@bib35]). Blocking PD-1 has a variety of CD4^+^ T cell effects. [@bib109] identified three specialized phenotypes of CD4^+^ memory T cells that expand in melanoma patients responding to PD-1 blockade. Additionally, CD4^+^CD57^+^ T cells, a senescent subset with limited proliferative capacity but high IFN-γ production, are decreased in biopsies from patients responding to anti--PD-1 therapy, but increased in nonresponders ([@bib89]). PD-L1 blockade during chronic viral infections causes a surfeit of PD-1^+^ T reg cells and reduces CD8^+^ T cell responsiveness. To counteract this, depletion of CD4^+^ T cells or T reg cells in combination with PD-L1 blockade revives exhausted CD8^+^ T cells and reduces viral load ([@bib76]). Collectively, CD4^+^ T cell help during PD-1 blockade may improve efficacy, but more studies are needed to define the impact of CD4^+^ T cells in tumor regression in the context of anti--PD-1/PD-L1 therapy.

Adverse events from immune checkpoint blockade {#s14}
==============================================

The cost of breaking tolerance is that checkpoint blockade treatment is accompanied by immune-related adverse events in ≤80% of patients ([@bib80]). Globally tampering with immune homeostasis causes autoimmune and inflammatory side effects involving the skin (pruritus and cutaneous rash), gastrointestinal tract (colitis and diarrhea), endocrine glands (hypophysitis and thyroid dysfunction) and liver (autoimmune hepatitis), although any organ system can be affected. The toxicity of anti--CTLA-4 therapy mirrors that of patients with loss-of-function mutations in CTLA-4 or the lipopolysaccharide-responsive and beige-like anchor protein, a critical regulator of CTLA-4 cell surface expression. These include autoantibody-mediated cytopenias, lymphocytic infiltration, and organ-specific autoimmunity ([@bib46]; [@bib55]). Effective management of these systemic disorders involves continuous monitoring and multidisciplinary collaboration to promptly diagnose and treat complications.

The adverse events resulting from CTLA-4 blockade differ from PD-1/PD-L1 inhibition in frequency, distribution, and toxicity because of the basic idea that CTLA-4 and PD-1 maintain tolerance in different ways. Anti--CTLA-4 therapy more commonly causes high-grade toxicity, especially severe and life-threatening colitis, whereas PD-1 inhibition has more tolerable side effects such as pneumonitis and hypothyroidism ([@bib31]; [@bib94]). Not surprisingly, patients who received ipilimumab and nivolumab combination therapy experienced a greater frequency (55%) of adverse events compared with either nivolumab (16.3%) or ipilimumab (27.3%) alone, although dual therapy was more successful therapeutically (see text box; [@bib48]). Severe, life-threatening reactions necessitate discontinuing therapy. Patients experiencing milder autoimmune reactions to immunotherapy often receive glucocorticoids to mitigate their symptoms. However, glucocorticoid treatment can be ineffective and has its own side effects, so other interventions have been deployed. Infliximab, an anti--TNF-α antibody commonly used for inflammatory bowel disease, was recently reported to completely resolve nivolumab-induced colitis ([@bib129]). An IL-17 inhibitor, already used for rheumatologic disease, has also been considered ([@bib27]); however, it is possible that IL-17 blockade could shackle antitumor efficacy ([@bib18]). Notably, a retrospective study found that cancer outcomes were unchanged by immunosuppressive therapies necessitated by adverse events, which supports an optimistic view that effective immunotherapy need not be sacrificed by controlling side effects ([@bib33]).

Combinatorial therapies {#s15}
-----------------------

Combining different treatment modalities designed to attack different vulnerabilities of the cancer cell and achieve synergism, i.e., combinatorial therapies, is a powerful concept in cancer treatment. Although checkpoint blockade revolutionized cancer therapy, not all patients respond or undergo complete remission, leaving room for new ideas. Combinatorial cancer therapy got a second wind from checkpoint inhibitors because they could be conjoined with conventional treatments as well as each other, both at the outset of newly diagnosed disease and when conventional modalities fail. This has improved response rates and long-term survival of cancer patients in several different trials. So augmenting T cell responsiveness during early activation as well as preventing a nonresponsive cell fate may synergize. Advanced melanoma patients treated with both ipilimumab and nivolumab responded at a rate of 61% compared with 11% in patients treated only with ipilimumab. Astoundingly, patients receiving combination therapy had a 22% complete response rate compared with no response in monotherapy patients ([@bib79]). Even more amazing is that combinations outperformed monotherapy even in patients with PD-L1--negative tumors, with an added 18 mo of survival ([@bib48]). The remarkable increase in efficacy using ipilimumab plus nivolumab led to FDA approval in 2015 to treat melanoma and, more recently, for renal cell carcinoma. These combinatorial successes confirm that CTLA-4 and PD-1 blockade circumvent peripheral tolerance through distinct molecular pathways, allowing synergy.

Other types of cancer therapies, notably radiation, may also help to improve clinical responses when combined with checkpoint blockade. Radiation damages tumor cells and generates neoantigens that are taken up by APCs to activate T cells in the lymph node ([@bib65]). Although this results in an increased diversity of the intratumoral TCR repertoire, radiotherapy may also impede antitumor immunity through PD-L1 up-regulation on tumor cells. Thus, radiation in combination with anti--PD-L1 antibody may further boost antitumor immunity, and preclinical trials have shown increased efficacy with this treatment strategy ([@bib16]; [@bib116]). Immune checkpoint blockade has also been shown to enhance the abscopal effect of radiation in patients with metastatic cancer ([@bib78]; [@bib24]; [@bib65]). The success of different combination therapies reveals the complexity of antitumor immunity as well as the immunosuppressive nature of the tumor microenvironment.

Conclusions {#s16}
===========

Over the past decade, immunotherapy has emerged as a new pillar of cancer treatment and provides renewed hope for reducing morbidity and mortality of this complex disease. Although the concept of using the immune system to fight cancer was theorized by Paul Ehrlich over a century ago ([@bib107]), a deep understanding of the mechanisms underlying antitumor immunity, particularly the role of T cells in immunity, was needed to achieve clinical success ([@bib61]). The discovery that CTLA-4 negatively regulates T cell signaling ([@bib122]), as well as the observation that inhibiting CTLA-4 results in rejection of preestablished tumors in mice ([@bib50]), were the underpinnings of an immunotherapeutic strategy that was the first to extend long-term survival of patients with advanced melanoma. Inhibition of PD-1, another negative regulator of T cells, proved to be an even more effective therapeutic than anti--CTLA-4. However, not all cancer types can be vanquished yet with checkpoint blockade or other types of cancer immunotherapy. Thus, while basic science research has changed the face of clinical oncology, efforts must continue to uncover molecular pathways that drive immune function and homeostasis. Although the baton of immunotherapy has been passed into the clinic, the history of this field has taught us that strong basic science efforts in the laboratory today are crucial to produce innovations at the bedside tomorrow.
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